|
1
|
Marras C and Chaudhuri KR: Nonmotor
features of Parkinson's disease subtypes. Mov Disord. 31:1095–1102.
2016.
|
|
2
|
Liu CL, Liao SJ, Zeng JS, Lin JW, Li CX,
Xie LC, Shi XG and Huang RX: dl-3n-butylphthalide prevents stroke
via improvement of cerebral microvessels in RHRSP. J Neurol Sci.
260:106–113. 2007.
|
|
3
|
Zhao Y, Lee JH, Chen D, Gu X, Caslin A, Li
J, Yu SP and Wei L: DL-3-n-butylphthalide induced neuroprotection,
regenerative repair, functional recovery and psychological benefits
following traumatic brain injury in mice. Neurochem Int. 111:82–92.
2017.
|
|
4
|
Jia J, Wei C, Liang J, Zhou A, Zuo X, Song
H, Wu L, Chen X, Chen S, Zhang J, et al: The effects of
DL-3-n-butylphthalide in patients with vascular cognitive
impairment without dementia caused by subcortical ischemic small
vessel disease: A multicentre, randomized, double-blind,
placebo-controlled trial. Alzheimers Dement. 12:89–99. 2016.
|
|
5
|
Cui LY, Zhu YC, Gao S, Wang JM, Peng B, Ni
J, Zhou LX, He J and Ma XQ: Ninety-day administration of
dl-3-n-butylphthalide for acute ischemic stroke: A randomized,
double-blind trial. Chin Med J (Engl). 126:3405–3410. 2013.
|
|
6
|
Huang JZ, Chen YZ, Su M, Zheng HF, Yang
YP, Chen J and Liu CF: dl-3-n-Butylphthalide prevents oxidative
damage and reduces mitochondrial dysfunction in an MPP(+)-induced
cellular model of Parkinson's disease. Neurosc Lett. 475:89–94.
2010.
|
|
7
|
Xiong N, Huang J, Chen C, Zhao Y, Zhang Z,
Jia M, Zhang Z, Hou L, Yang H, Cao X, et al: Dl-3-n-butylphthalide,
a natural antioxidant, protects dopamine neurons in rotenone models
for Parkinson's disease. Neurobiol Aging. 33:1777–1791. 2012.
|
|
8
|
Hughes AJ, Daniel SE, Kilford L and Lees
AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's
disease: A clinico-pathological study of 100 cases. J Neurol
Neurosurg Psychiatry. 55:181–184. 1992.
|
|
9
|
Corcos DM, Robichaud JA, David FJ,
Leurgans SE, Vaillancourt DE, Poon C, Rafferty MR, Kohrt WM and
Comella CL: A two-year randomized controlled trial of progressive
resistance exercise for Parkinson's disease. Mov Disord.
28:1230–1240. 2013.
|
|
10
|
Schiess MC, Zheng H, Soukup VM, Bonnen JG
and Nauta HJ: Parkinson's disease subtypes: Clinical classification
and ventricular cerebrospinal fluid analysis. Parkinsonism Relat
Disord. 6:69–76. 2000.
|
|
11
|
Thomas S, Reading J and Shephard RJ:
Revision of the physical activity readiness questionnaire (PAR-Q).
Can J Sport Sci. 17:338–345. 1992.
|
|
12
|
Volta M, Milnerwood AJ and Farrer MJ:
Insights from late-onset familial parkinsonism on the pathogenesis
of idiopathic Parkinson's disease. Lancet Neurol. 14:1054–1064.
2015.
|
|
13
|
Calabresi P and Di Filippo M: Multitarget
disease-modifying therapy in Parkinson's disease? Lancet Neurol.
14:975–976. 2015.
|
|
14
|
Spiegel J, Möllers MO, Jost WH, Fuss G,
Samnick S, Dillmann U, Becker G and Kirsch CM: FP-CIT and MIBG
scintigraphy in early Parkinson's disease. Mov Disord. 20:552–561.
2005.
|
|
15
|
Ahlskog JE: Diagnosis and differential
diagnosis of Parkinson's disease and parkinsonism. Parkinsonism
Relat Disord. 7:63–70. 2000.
|
|
16
|
Chiaravalloti A, Stefani A, Tavolozza M,
Pierantozzi M, Di Biagio D, Olivola E, Di Pietro B, Stampanoni M,
Danieli R, Simonetti G, et al: Different patterns of cardiac
sympathetic denervation in tremor-type compared to
akinetic-rigid-type Parkinson's disease: Molecular imaging with
¹23I-MIBG. Mol Med Rep. 6:1337–1342. 2012.
|
|
17
|
Schillaci O, Chiaravalloti A, Pierantozzi
M, Di Pietro B, Koch G, Bruni C, Stanzione P and Stefani A:
Different patterns of nigrostriatal degeneration in tremor type
versus the akinetic-rigid and mixed types of Parkinson's disease at
the early stages: Molecular imaging with 123I-FP-CIT SPECT. Int J
Mol Med. 28:881–886. 2011.
|
|
18
|
Shannon KM, Keshavarzian A, Dodiya HB,
Jakate S and Kordower JH: Is alpha-synuclein in the colon a
biomarker for premotor Parkinson's disease? Evidence from 3 cases.
Mov Disord. 27:716–719. 2012.
|
|
19
|
Espay AJ, LeWitt PA and Kaufmann H:
Norepinephrine deficiency in Parkinson's disease: The case for
noradrenergic enhancement. Mov Disord. 29:1710–1719. 2014.
|
|
20
|
Zhao J, Liu J, Xu E, Liu Y, Xie A and
Xiong H: dl-3-n-Butylphthalide attenuation of
methamphetamine-induced neurotoxicity in SH-SY5Y neuroblastoma
cells. Life Sci. 165:16–20. 2016.
|
|
21
|
Zhou J, Zhang YH, Song HZ, Ji H, Wang XL,
Wang L, Qian J, Ling JJ and Ping FF: 5d, a novel analogue of
3-n-butylphthalide, decreases NADPH oxidase activity through the
positive regulation of CK2 after ischemia/reperfusion injury.
Oncotarget. 7:39444–39457. 2016.
|
|
22
|
Liu K, Huang J, Chen R, Zhang T, Shen L,
Yang J and Sun X: Protection against neurotoxicity by an autophagic
mechanism. Braz J Med Biol Res. 45:401–407. 2012.
|
|
23
|
Qin L, Wu X, Block ML, Liu Y, Breese GR,
Hong JS, Knapp DJ and Crews FT: Systemic LPS causes chronic
neuroinflammation and progressive neurodegeneration. Glia.
55:453–462. 2007.
|
|
24
|
Pal GD, Shaikh M, Forsyth CB, Ouyang B,
Keshavarzian A and Shannon KM: Abnormal lipopolysaccharide binding
protein as marker of gastrointestinal inflammation in Parkinson
disease. Front Neurosci. 9:3062015.
|
|
25
|
Hand TW, Vujkovic-Cvijin I, Ridaura VK and
Belkaid Y: Linking the microbiota, chronic disease, and the immune
system. Trends Endocrinol Metab. 27:831–843. 2016.
|
|
26
|
Sampson TR, Debelius JW, Thron T, Janssen
S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S,
Gradinaru V, et al: Gut microbiota regulate motor deficits and
neuroinflammation in a model of Parkinson's disease. Cell.
167:1469–1480.e12. 2016.
|
|
27
|
McCann H, Cartwright H and Halliday GM:
Neuropathology of α-synuclein propagation and braak hypothesis. Mov
Disord. 31:152–160. 2016.
|
|
28
|
Yang Q, Hu YD, Wang XF and Zheng FS:
Dl-3n-butylphthalide reduces epileptiform activity through
GluA2-lacking calcium-permeable AMPARs in epilepsy models.
Oncotarget. 8:98242–98257. 2017.
|
